Symbol="OKYO"
AssetType="Common Stock"
Name="OKYO Pharma Ltd ADR"
Description="OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom."
CIK="1849296"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="55 PARK LANE, LONDON, GB"
FiscalYearEnd="March"
LatestQuarter="2023-03-31"
MarketCapitalization="43383700"
EBITDA="-7134629"
PERatio="None"
PEGRatio="None"
BookValue="-0.014"
DividendPerShare="0"
DividendYield="0"
EPS="-0.01"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-1.547"
ReturnOnEquityTTM="-3.971"
RevenueTTM="0"
GrossProfitTTM="-3599629"
DilutedEPSTTM="-0.01"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="None"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="12.91"
EVToRevenue="-"
EVToEBITDA="-7.01"
Beta="-2.909"
num_52WeekHigh="3.74"
num_52WeekLow="0.92"
num_50DayMovingAverage="1.347"
num_200DayMovingAverage="1.788"
SharesOutstanding="25519800"
DividendDate="None"
ExDividendDate="None"
symbol="OKYO"
open="1.64"
high="1.74"
low="1.50"
price="1.55"
volume="72772.00"
latest_trading_day="2023-08-17"
previous_close="1.70"
change="-0.15"
change_percent="-8.8235%"
aroon_positive_momentum_days="37"
aroon_negative_momentum_days="0"
trend_strength="Strong Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="37"
Volume_recent_avg="122684"
Change_recent_avg="0.02"
Delta_recent_avg="0.2"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="0.91"
RSI_change="FALSE"
ADX_change="FALSE"

event="aroon_milestone_positive_10"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="37"
Aroon_momentum_negative="63"
image_negative_thumbnail_id_1="496"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0109.jpeg"
image_negative_thumbnail_id_2="1122"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0155.jpeg"
image_neutral_thumbnail_id_1="583"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_neutral_thumbnail_id_2="593"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0006.jpeg"
image_positive_thumbnail_id_1="643"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0065.jpeg"
image_positive_thumbnail_id_2="1005"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0167.jpeg"
image_professor_thumbnail_id_1="1201"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
image_professor_thumbnail_id_2="1172"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
